These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16447341)

  • 21. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience.
    Ortiz-Prado E; Cevallos-Sierra G; Teran E; Vasconez E; Borrero-Maldonado D; Ponce Zea J; Simbaña-Rivera K; Gómez-Barreno L
    Expert Opin Ther Pat; 2019 Aug; 29(8):653-662. PubMed ID: 31298053
    [No Abstract]   [Full Text] [Related]  

  • 23. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceuticals: pharmaceutical cost controls.
    Seay M; Lee LL
    Issue Brief Health Policy Track Serv; 2007 Jan; ():1-22. PubMed ID: 17357250
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global health and university patents.
    Kapczynski A; Crone ET; Merson M
    Science; 2003 Sep; 301(5640):1629. PubMed ID: 14500943
    [No Abstract]   [Full Text] [Related]  

  • 27. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 29. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.
    Grabowski H; Vernon J
    Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The link between publicly funded health care and compulsory licensing.
    Hollis A
    CMAJ; 2002 Oct; 167(7):765-6. PubMed ID: 12389839
    [No Abstract]   [Full Text] [Related]  

  • 31. India moves closer to regulating prices of patented drugs.
    Kay M
    BMJ; 2014 Jan; 348():g1244. PubMed ID: 24480395
    [No Abstract]   [Full Text] [Related]  

  • 32. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are rich nations up for drug reform?
    Check E
    Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA milestones.
    FDA Consum; 2006; 40(1):36-8. PubMed ID: 16528826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brazil's AIDS controversy: antiretroviral drugs, breaking patents, and compulsory licensing.
    Marques UR; Guimarães VS; Sternberg C
    Food Drug Law J; 2005; 60(3):471-7. PubMed ID: 16304752
    [No Abstract]   [Full Text] [Related]  

  • 37. [40 years of medicines policy in the Netherlands: from financial constraints to medicines shortages?].
    Steenhoek A; Koopmanschap M; Piepenbrink JF
    Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
    [No Abstract]   [Full Text] [Related]  

  • 39. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmaceutical specialities: definitions and rules for manufacturing and marketing in Italy].
    Germani C; Montanari L; Petraroja A
    Boll Chim Farm; 1979 Mar; 118(3):135-43. PubMed ID: 475905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.